Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

Electronic health record maker NextGen Healthcare to pay $31 million to resolve fraud claims

The health records company NextGen Healthcare will pay $31 million to resolve allegations that it paid kickbacks to win customers and concealed shortcomings of its

July 17, 2023

“Cleaning cell” dysfunction explains unequal diabetes risk in obesity

Disrupted function of “cleaning cells” in the body may help to explain why some people with obesity develop type 2 diabetes, while others do not.

February 5, 2024

AstraZeneca, Daiichi Sankyo eye first approval for TROP2 drug after PhIII breast cancer success

AstraZeneca and Daiichi Sankyo’s TROP2-targeted antibody-drug conjugate has met a key endpoint in the Phase III TROPION-Breast01 trial, bringing it one step closer to potentially compete

September 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.